Avacta GroupAVCTF 13 Cash Ratio is 0.64 as of Dec. 2025, which is 75% below its 10-year median of 2.56. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,386 Biotechnology companies, Avacta Group ranks worse than 79.73% on this metric.
Avacta Group has a Cash Ratio of 0.64. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Avacta Group's Cash Ratio or its related term are showing as below:
AVCTF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.33 Med: 2.56 Max: 12.67
Current: 0.64
During the past 13 years, Avacta Group's highest Cash Ratio was 12.67. The lowest was 0.33. And the median was 2.56.
AVCTF's Cash Ratio is ranked worse than 79.73% of 1386
companies
in the Biotechnology industry
Industry Median: 2.93
vs AVCTF: 0.64
Avacta Group (OTCPK:AVCTF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Avacta Group Cash Ratio Related Terms
Avacta Group Cash Ratio Historical Data
* Premium members only.
The historical data trend for Avacta Group's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avacta Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Avacta Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Cash Ratio of 0.64 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avacta Group and its competitors. This is 75% below median its historical median of 2.56. Over the past decade, Avacta Group's Cash Ratio has ranged from 0.33 to 12.67. According to the industry distribution chart, Avacta Group ranks #1105 out of 1386 companies in the Biotechnology industry, placing it in the top 79.7%.
Is Avacta Group's Cash Ratio too high?
Avacta Group's current Cash Ratio of 0.64 is 75% below median its 10-year median of 2.56. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 12.67. The Biotechnology industry median Cash Ratio is 2.93. Avacta Group's value of 0.64 is 78.2% below this industry median. Based on the distribution chart, Avacta Group ranks #1105 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #1105 out of 1386 companies for Cash Ratio. This places Avacta Group in the lower half of its industry. The industry median Cash Ratio is 2.93. Avacta Group's value of 0.64 is 78.2% below this benchmark. Historically, Avacta Group's own Cash Ratio has ranged from 0.33 to 12.67 over the past decade. While the company's 10-year median is 2.56 vs. the industry median of 2.93, Avacta Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Cash Ratio of 0.64 is 78.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Cash Ratio is 0.64, which is 75% below median its own 10-year median of 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $1.00 — trading 53.8% above its estimated fair value. The current Cash Ratio is 0.64, which is 75% below median its 10-year median of 2.56 and 78.2% below the Biotechnology industry median of 2.93. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Cash Ratio is 0.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 53.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Cash Ratio: 0.64 (75% below median its 10-year median of 2.56)
GF Value™: $0.65 vs. price of $1.00 (53.8% above fair value)
Industry Position: 78.2% below the Biotechnology median (#1105 of 1386)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
